Safety of early chemotherapy after a laparoscopic colorectal cancer resection: A case-control study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, S.H. | - |
dc.contributor.author | Lee, S.-I. | - |
dc.contributor.author | Choi, D.-J. | - |
dc.contributor.author | Woo, S.-U. | - |
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Min, B.-W. | - |
dc.contributor.author | Moon, H.-Y. | - |
dc.contributor.author | Kim, S.H. | - |
dc.date.accessioned | 2021-09-09T00:32:54Z | - |
dc.date.available | 2021-09-09T00:32:54Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 2093-7822 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/121932 | - |
dc.description.abstract | Purpose: Since micrometastasis is generally inhibited by primary cancer, surgical ablation of the tumor may stimulate the growth of residual cancer cells, if they exist. This supports the importance of early administration of postoperative chemotherapy. Methods: We reviewed the cases of patients who underwent a laparoscopic resection and then received chemotherapy (5 fluorouracil+leucovorin or FOLFOX4) between September 2006 and May 2008. The chemotherapy was scheduled on the 7th or the 8th postoperative day, but was postponed when a final pathologic report was delayed or patients were discharged early. The safety of chemotherapy was evaluated in two ways. Early safety, such as the presence of surgical complications and medical toxicity, was prospectively assessed just before the beginning of the second cycle of chemotherapy. Late safety, such as medical toxicity, was retrospectively estimated from the 2nd to the last cycle. These safeties were compared between the two groups: the early chemotherapy group (n=50) for which chemotherapy started on the 7th or 8th postoperative day as scheduled and the delayed chemotherapy group (n=31) for which chemotherapy started after the 14th postoperative day. Results: Patient demographics were not different between the two groups. With regards to early safety, no differences in surgical complications existed between the two groups. In medical toxicities, there were no differences, except for a higher rate of nausea in the early chemotherapy group (20 percent vs. 10 percent, P=0.01). With regards to late safety, the two groups were not different in the development of medical toxicities. Conclusion: Because nausea is an easily controllable toxicity, we conclude that chemotherapy is safely started on the 7th or the 8th day after a laparoscopic colorectal cancer resection. ©2009 The Korean Society of Coloproctology. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.subject | fluorouracil | - |
dc.subject | folinic acid | - |
dc.subject | adult | - |
dc.subject | article | - |
dc.subject | cancer combination chemotherapy | - |
dc.subject | cancer surgery | - |
dc.subject | case control study | - |
dc.subject | colorectal cancer | - |
dc.subject | colorectal surgery | - |
dc.subject | drug dose regimen | - |
dc.subject | drug safety | - |
dc.subject | early intervention | - |
dc.subject | female | - |
dc.subject | human | - |
dc.subject | laparoscopic surgery | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | multimodality cancer therapy | - |
dc.subject | multiple cycle treatment | - |
dc.subject | nausea | - |
dc.subject | postoperative care | - |
dc.subject | postoperative complication | - |
dc.subject | therapy delay | - |
dc.title | Safety of early chemotherapy after a laparoscopic colorectal cancer resection: A case-control study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, S.-I. | - |
dc.contributor.affiliatedAuthor | Kim, J. | - |
dc.contributor.affiliatedAuthor | Min, B.-W. | - |
dc.contributor.affiliatedAuthor | Kim, S.H. | - |
dc.identifier.doi | 10.3393/jksc.2009.25.6.429 | - |
dc.identifier.scopusid | 2-s2.0-77953393722 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Society of Coloproctology, v.25, no.6, pp.429 - 436 | - |
dc.relation.isPartOf | Journal of the Korean Society of Coloproctology | - |
dc.citation.title | Journal of the Korean Society of Coloproctology | - |
dc.citation.volume | 25 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 429 | - |
dc.citation.endPage | 436 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001409156 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | fluorouracil | - |
dc.subject.keywordPlus | folinic acid | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer combination chemotherapy | - |
dc.subject.keywordPlus | cancer surgery | - |
dc.subject.keywordPlus | case control study | - |
dc.subject.keywordPlus | colorectal cancer | - |
dc.subject.keywordPlus | colorectal surgery | - |
dc.subject.keywordPlus | drug dose regimen | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | early intervention | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | laparoscopic surgery | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multimodality cancer therapy | - |
dc.subject.keywordPlus | multiple cycle treatment | - |
dc.subject.keywordPlus | nausea | - |
dc.subject.keywordPlus | postoperative care | - |
dc.subject.keywordPlus | postoperative complication | - |
dc.subject.keywordPlus | therapy delay | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Colorectal cancer | - |
dc.subject.keywordAuthor | Laparoscopic resection | - |
dc.subject.keywordAuthor | Safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.